Press "Enter" to skip to content

Novartis buys Takeda’s dry eye drug for $3.4 bln

Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd’s dry eye drug Xiidra for an upfront payment of $3.4 billion to expand its portfolio of eye care medicines.

Original source:

Also Read:   Bharat Biotech looks to expand phase-III trial base